Unlocking a New Generation of CNS-Targeted Therapies

Uniting Global Biopharma Leaders to Advance the Next Generation of Brain Delivery Technologies

Long regarded as one of the greatest barriers to successful CNS drug development, brain delivery is finally entering a new era of clinical validation. Following Denali's Avlayah becoming the first FDA-approved therapy leveraging blood-brain barrier (BBB) shuttle technology, alongside encouraging advancements from Roche's Trontinemab, the industry now has clear proof that receptor-mediated transport can unlock meaningful CNS exposure for biologics. This breakthrough is accelerating investment, partnerships, and innovation across brain shuttles, targeted vectors, oligonucleotide delivery, focused ultrasound, intrathecal systems, and next-generation CNS delivery platforms.

Yet major challenges remain. Developers must still improve brain exposure, demonstrate clinical translatability, optimize biodistribution, de-risk toxicity, scale manufacturing, and establish clear advantages over conventional CNS delivery routes. As programs progress beyond transferrin receptor targeting and explore novel BBB receptors, advanced imaging technologies, humanized translational models, and innovative delivery modalities, cross-functional collaboration has become essential to translating promising technologies into approved therapies.

Bringing together 100+ senior leaders spanning neuroscience, biologics, protein engineering, drug delivery, DMPK, translational sciences, platform development, chemistry, business development, and investment, the 8th CNS Drug Delivery Summit is the industry's definitive forum dedicated to overcoming the delivery challenge. Join experts from Roche, Novartis, Eli Lilly, AbbVie, Alnylam, Bristol Myers Squibb, Lundbeck, Voyager Therapeutics, Biogen, Stoke Therapeutics, UCB, Harvard, JCR Pharmaceuticals and more to explore the latest BBB shuttle readouts, emerging receptor targets beyond TfR1, biodistribution and imaging innovations, focused ultrasound technologies, gene therapy delivery advances, and the investment landscape shaping the future of CNS therapeutics.